Moberg Pharma

10.90 SEK

-2.33 %

Less than 1K followers

MOB

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

-2.33 %
+3.81 %
+17.27 %
+6.13 %
+39.92 %
+39.12 %
-34.86 %
-69.04 %
-81.76 %

Moberg Pharma is a Swedish pharmaceutical company with a focus on commercialization of proprietary drugs based on proven substances. The company works primarily in nail fungus, where Moberg Pharma is developing a topical treatment. Moberg Pharma has agreements with commercial partners in place in Europe and Canada, among other places. The company's headquarters are located in Bromma.

Read more
Market cap
530.96M SEK
Turnover
1.89M SEK
Revenue
13.54M
EBIT %
-201.77 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
12/5
2026

Interim report Q1'26

21/5
2026

General meeting '26

13/8
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Moberg Pharma Sidan kunde inte hittas Page not found A major blow: according to preliminary data, the drug’s efficacy is weaker than expected. The press release still leaves some things open to speculation, but the market has already drawn its conclusions.
9/13/2024, 7:55 AM
by Clark kent
7
Interim Report May 7th Moberg Pharma Sidan kunde inte hittas Page not found Some sales are already happening in Sweden. Marketing authorizations have now been received in all 13 EU countries that participated in the licensing process, and Terclara is coming to market over-the-counter...
5/9/2024, 9:32 AM
by Makee
5
A press release was issued yesterday stating that sales have (finally) started in Sweden and it’s apparently available in most pharmacies now. Sidan kunde inte hittas | Moberg Pharma. It is also available for order from online pharmacies without a prescription, and the price seems...
2/8/2024, 4:48 PM
by Makee
5
The conference call recording has now been published on Moberg’s website: Sidan kunde inte hittas | Moberg Pharma In my opinion, it didn’t provide much additional information: -They are not publishing patient numbers or percentages because they want to “protect” the blinded data ...
9/13/2024, 3:56 PM
by Makee
3
We should think about this from the customer’s, i.e., the patient’s, perspective. They notice that the “nail is ugly.” The doctor sees the same thing. They consider whether the nail is damaged or if there is fungus. A culture is taken. The result is positive, and treatment begins...
1/2/2024, 1:05 PM
by Vino Pino
3
After the USA disappointment, the strategy is now the EU. The market has punished. Jan-Mar Oct-Dec Jul-Sep Apr-Jun Jan-Mar 2025 2024 2024 2024 2024 values in thousands SEK Net revenue 3,869 1,027 3,855 4,109 820 Cost of goods sold -1,304 -1,165 -615 -1,388 -328 Gross profit 2,565...
5/21/2025, 7:49 AM
by Clark kent
2
It could very well be an alternative. In your table, the figures do not convince me of its superiority. By the appearance of the nail, I meant how it looks after the treatment, i.e., it hasn’t healed. As an additional problem, it is mentioned there that terbinafine discolors the ...
1/2/2024, 3:14 PM
by Vino Pino
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.